Clinical trials: Gastric/Esophageal Cancer
Gastroesophageal Junction Adenocarcinoma, Adenocarcinoma of the Stomach
Avelumab + Paclitaxel/ Ramucirumab (RAP) as Second Line Treatment in Gastro-esophageal Adenocarcinoma
Avelumab + Paclitaxel/ Ramucirumab as second line treatment in gastro-esophageal adenocarcinoma following first-line therapy with platinum and fluoropyrimidine doublet with or without anthracycline, docetaxel or trastuzumab
- Trial name
- AIO-STO-0218 (NCT03966118)
- Testing
- Avelumab, Ramucirumab, Paclitaxel
- Where
- Germany
- Volunteers
- 59 people
- Sponsor
- P. C. Thuss-Patience
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction
C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer
This partially randomized phase I/II trial studies the side effects and best dose of c-Met inhibitor AMG 337 when given together with oxaliplatin, leucovorin calcium, and fluorouracil and to see how well they work in treating…
- Conditions
- Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Gastrointestinal Cancer
- Trial name
- NCT02344810
- Testing
- c-Met inhibitor AMG 337, oxaliplatin, leucovorin calcium
- Where
- United States
- Sponsor
- Eastern Cooperative Oncology Group
Pancreatic Cancer, Small Bowel Cancer
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
The objective of this expanded access program is to provide ulixertinib (BVD-523) for compassionate use in advanced cancer patients with MAPK pathway-altered solid tumor(s), including but not limited to KRAS, NRAS, HRAS, BRAF…
- Conditions
- Pancreatic Cancer, Small Bowel Cancer, Colorectal Cancer, Melanoma
- Trial name
- NCT04566393
- Testing
- Ulixertinib (BVD-523)
- Where
- 26 sites in United States
- Sponsor
- xCures
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction
Erlotinib Hydrochloride in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer
This phase II trial is studying erlotinib hydrochloride to see how well it works in treating patients with advanced esophageal cancer or stomach cancer.
- Conditions
- Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Recurrent Esophageal Cancer, Squamous Cell Carcinoma of the Esophagus
- Trial name
- NCT00045526
- Testing
- erlotinib hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- National Cancer Institute (NCI)
Gastrointestinal Cancer, Cholangiocarcinoma
Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients
This study aims to find out: 1. The tolerability of Cabotamig (ARB202) in adults with advanced solid gastrointestinal tumors who failed the standard treatment. People can participate if their tumor has the CDH17 marker. 2.
- Conditions
- Gastrointestinal Cancer, Cholangiocarcinoma, Liver Cancer, Colorectal Adenocarcinoma
- Trial name
- NCT05411133
- Testing
- Cabotamig (ARB202)
- Where
- 3 sites in Australia, Hong Kong
- Volunteers
- 33 people
- Sponsor
- Arbele Pty Ltd
Pancreatic Cancer, Colon Cancer
Cancer Loyalty Card Study 2 (CLOCS-2)
Cancer is one of the leading causes of mortality worldwide and is responsible for an estimated 9.6 million deaths yearly. Cancer-related deaths can be reduced if patients are diagnosed and treated early.
- Conditions
- Pancreatic Cancer, Colon Cancer, Oesophageal Cancer, Stomach Cancer
- Trial name
- (CLOCS-2) (NCT06447064)
- Testing
- Cases & Controls
- Where
- United Kingdom
- Volunteers
- 2,900 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Metastatic Gastric Cancer, Adenocarcinoma of the Gastro-oesophageal Junction
Docetaxel, Oxaliplatin, Capecitabine, Bevacizumab and Trastuzumab in Patients With Locally Advanced or Metastatic Gastric Cancer
Background: It is estimated that in the Netherlands each year approximately 900 patients with gastric cancer or adenocarcinoma of the gastro-oesophageal junction are candidates for chemotherapy.
- Trial name
- B-DOCT (NCT01359397)
- Testing
- Docetaxel, Oxaliplatin, Capecitabin, Bevacizumab, Docetaxel, Oxaliplatin, Capecitabin, Bevacizumab, Trastuzumab
- Where
- Netherlands
- Sponsor
- The Netherlands Cancer Institute
Solid Tumor, KRAS Mutation
A Study to Test How Well Different Doses of BI 3706674 Are Tolerated by People With Advanced Cancer in the Stomach and Oesophagus
This study is no longer open to new participants. It was a study in adults with advanced cancer in the stomach and oesophagus. This is a study for people for whom previous treatment was not successful or no treatment exists.
- Trial name
- NCT06056024
- Testing
- BI 3706674
- Where
- 17 sites in United States, Japan and 2 more
- Volunteers
- 47 people
- Sponsor
- Boehringer Ingelheim
Cancer
Massage Therapy in Treating the Symptoms of Patients With Locally Advanced or Metastatic Cancer
RATIONALE: Massage therapy may help relieve symptoms associated with cancer. It is not yet known which type of massage therapy is more effective in treating the symptoms of patients with cancer.
- Trial name
- NCT00253708
- Testing
- management of therapy complications, massage therapy, pain therapy
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Beth Israel Deaconess Medical Center
Cancer of Pancreas, Cancer of Stomach
Wet Heparinized Suction for Abdominal Cancer
The purpose of this research is to compare the amount and quality of tissue obtained by EUS-FNB when the device is flushed with an anticoagulant or "blood thinner" vs.
- Conditions
- Cancer of Pancreas, Cancer of Stomach, Cancer of Esophagus, Cancer of Liver
- Trial name
- EUS Heparin (NCT05041335)
- Testing
- wet heparinzed suction, Microsieve, No heparin flush
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Pancreatic Cancer, Breast Cancer
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
Study of NGM831 as Monotherapy and in Combination with Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
- Conditions
- Pancreatic Cancer, Breast Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT05215574
- Testing
- NGM831, NGM831 plus pembrolizumab (KEYTRUDA®), NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®)
- Where
- 9 sites in United States
- Volunteers
- 130 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Gastric Cancer, Esophageal Neoplasms
Study of T900607-Sodium in Subjects With Previously Treated Gastric Cancer or Adenocarcinoma of the Esophagus
This is a clinical research study of T900607-sodium to determine if it is effective and safe in treating gastric cancer and adenocarcinoma of the esophagus.
- Trial name
- NCT00048529
- Testing
- T900607-sodium intravenous
- Where
- 5 sites in United States
- Volunteers
- 70 people
- Sponsor
- Tularik
Mesothelioma, Glioblastoma
Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
- Conditions
- Mesothelioma, Glioblastoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer
- Trial name
- NCT04913337
- Testing
- NGM707, NGM707 plus pembrolizumab (KEYTRUDA®)
- Where
- 27 sites in United States, South Korea and 1 more
- Volunteers
- 179 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Esophageal Cancer, Surgery Indication
Evaluation of the Administration of Artificial Nutrition by Feeding Jejunostomy During Neoadjuvant Treatment on Postoperative Morbidity in the Context of Esophageal or Stomach Cancer
Malnutrition is common at the time of diagnosis of esogastric cancers. However, there are no recommendations regarding preoperative nutritional support (type and duration) or on the impact of refeeding on postoperative morbidity…
- Conditions
- Esophageal Cancer, Surgery Indication, Malnourished, Neoadjuvant Treatment
- Trial name
- FREJENO (NCT07584577)
- Testing
- Enteral or parenteral nutrition
- Where
- France
- Volunteers
- 670 people
- Sponsor
- University Hospital, Bordeaux
Esophageal Cancer, Gastric Cancer
Oxaliplatin and Capecitabine in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00040859
- Testing
- capecitabine, oxaliplatin
- Where
- 6 sites in United States
- Volunteers
- 48 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Cancer of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction
A Trial of ZD6474, Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiation Therapy Followed by Surgery
The purpose of the study is to determine the most tolerable and safe dose of ZD6474 (Zactima, Vandetanib) when given with standard chemotherapy, radiation therapy and surgery in patients with cancer of the esophagus
- Conditions
- Cancer of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Cancer of the Stomach
- Trial name
- NCT01183559
- Testing
- Vandetanib, 5 Fluorouracil (FU), Carboplatin
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Fox Chase Cancer Center
Gastroesophageal Cancer (GC), Postoperative Delirium (POD)
Cognitive Impact Associated With Surgery For Gastric Or Esophageal Cancer
The primary objective of this observational study is to investigate the incidence of Post Operative Delirium (POD) after gastroesophageal cancer surgery.
- Conditions
- Gastroesophageal Cancer (GC), Postoperative Delirium (POD), Quality of Life (QOL), Frailty
- Trial name
- CASE (NCT06687291)
- Where
- Sweden
- Volunteers
- 130 people
- Sponsor
- Karolinska Institutet
Gastric Adenocarcinoma, Esophagus Adenocarcinoma
Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer
Oxaliplatin ± nivolumab in combination with trifluridine/tipiracil or 5-fluorouracile (5-FU) in frail patients with advanced, recurrent or metastatic gastric, oesophageal or gastroesophageal junction cancer.
- Conditions
- Gastric Adenocarcinoma, Esophagus Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- Trial name
- LOGICAN (NCT05476796)
- Testing
- Trifluridine/Tipiracil, Oxaliplatin, FOLFOX regimen
- Where
- 28 sites in France
- Volunteers
- 118 people
- Sponsor
- UNICANCER
Gastric Cancer, Adenocarcinoma of the Stomach
Radiomics and Molecular Expression Predictive Model for Esophago-Gastric Junction and Gastric Cancer TRG
The aim of this study is to develop a CT scan-based radiomics predictive model about tumor regression grade (TRG) in patients with esophago-gastric junction (EGJ) ang gastric cancer undergoing perioperative chemotherapy.
- Trial name
- NCT04878783
- Testing
- CT scan
- Where
- 5 sites in Italy, Netherlands
- Volunteers
- 138 people
- Sponsor
- University of Roma La Sapienza
Advanced or Metastatic Solid Tumors
Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
This is a first-in-human, open-label, multicenter, Phase 1 study to evaluate the safety, tolerability and preliminary efficacy of IPH4502 and to determine the recommended Phase 2 dose (RP2D) in advanced solid tumors that are…
- Trial name
- NCT06781983
- Testing
- IPH4502
- Where
- 7 sites in United States, France
- Volunteers
- 145 people
- Sponsor
- Innate Pharma